Powder: -20°C for 3 years | In solvent: -80°C for 1 year
I-CBP112 hydrochloride 是含溴结构域转录因子的选择性抑制剂,靶向 CBP/p300 溴结构域。在体内外,它以剂量依赖性方式显着降低 MLL-AF9(+) 急性髓细胞白血病细胞的白血病起始潜力,还增加 BET 溴结构域抑制剂 JQ1 以及阿霉素的细胞毒活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 798 | 现货 | ||
2 mg | ¥ 1,450 | 现货 | ||
5 mg | ¥ 2,410 | 现货 | ||
10 mg | ¥ 3,590 | 现货 | ||
25 mg | ¥ 5,820 | 现货 | ||
50 mg | ¥ 7,930 | 现货 | ||
100 mg | ¥ 10,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 4,560 | 现货 |
产品描述 | I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors. I-CBP112 (1 mM) has little activity against other bromodomains. I-CBP112 targets the CBP/p300 bromodomains. I-CBP112 significantly reduced the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. Interestingly, I-CBP112 increased the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin. |
体外活性 | I-CBP112 markedly increases acetylation by p300 at the histone H3K18 and H3K23 sites. I-CBP112 stimulated H3K18ac by ~3-fold, and induced enhances acetylation of these same sites by CBP as well as at H4K5. The EC50s of activation of I-CBP112 on CBP- and p300-mediated H3K18 acetylation are ~2 μM[1]. In mouse and human leukemia cell lines, I-CBP112 causes substantially impaired colony formation and induces cellular differentiation without significant cytotoxicity. In BioMAP primary cell panel, I-CBP112 results in a unique response on cytokine and marker protein expression[2]. |
体内活性 | I-CBP112 markedly and dose-dependently reduces the leukemia-initiating potential of mLL-AF9+ AmL cells in vitro and in vivo. The synergistic effects of I-CBP112 and current standard therapy (doxorubicin), as well as emerging treatment strategies (BET inhibition), provide new possibilities for combinatorial treatment of leukemia and potentially other cancers[2]. |
分子量 | 505.05 |
分子式 | C27H37ClN2O5 |
CAS No. | 2147701-33-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (118.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.98 mL | 9.9 mL | 19.8 mL | 49.5 mL |
5 mM | 0.396 mL | 1.98 mL | 3.96 mL | 9.9 mL | |
10 mM | 0.198 mL | 0.99 mL | 1.98 mL | 4.95 mL | |
20 mM | 0.099 mL | 0.495 mL | 0.99 mL | 2.475 mL | |
50 mM | 0.0396 mL | 0.198 mL | 0.396 mL | 0.99 mL | |
100 mM | 0.0198 mL | 0.099 mL | 0.198 mL | 0.495 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
I-CBP112 hydrochloride 2147701-33-3 Chromatin/Epigenetic Epigenetic Reader Domain inhibit Inhibitor I CBP112 hydrochloride I-CBP 112 Hydrochloride I-CBP-112 hydrochloride I-CBP112 I-CBP112 Hydrochloride I-CBP-112 Hydrochloride ICBP112 hydrochloride inhibitor